We are generating several families of anticancer drugs that act on the cell cycle, including cyclin dependent kinase (CDK) and Aurora kinase (AK) inhibitors. We are advancing three of our anticancer drug candidates, sapacitabine, seliciclib and CYC116 through in-house research and development activities. We have eight further novel drug series: five for cancer, one for inflammatory kidney disease, one for HIV/AIDS and one for Type 2 Diabetes. Taken together, our pipeline covers all four phases of the cell cycle, which we believe will improve the chances of successfully developing and commercializing novel drugs that work on their own or in combination with approved conventional chemotherapies or with other targeted drugs to treat human cancers.
| Oncology Programs | CYC | Indication | Stage | Rights |
|---|---|---|---|---|
| Sapacitabine | 682 | AML | Phase 2 | Cyclacel |
| MDS | Phase 2 | Cyclacel | ||
| NSCLC | Phase 2 | Cyclacel | ||
| Seliciclib | 202 | NSCLC | Phase 2 | Cyclacel |
| NPC | Phase 2 | Cyclacel | ||
| Sapacitabine + seliciclib | 682+202 | Solid Tumors | Phase 1 | Cyclacel |
| CYC116 | 116 | Solid Tumors | Phase 1 | Cyclacel |
NB: NSCLC = non-small cell lung cancer, NPC = nasopharyngeal cancer, MDS = myelodysplastic syndromes